Table 1.

Observations reporting on clinical outcome of VFL in daily clinical practice since the drug’s approval in 2009.

Author	Number of observed patients	OS/PFS (months)
Pistamaltzian et al. [2016]	n = 71, retrospective study	11.9/6.9
Moriceau et al. [2015]	n = 19, retrospective study	4.0/2.9
Medioni et al. [2016]	n = 134, retrospective study	8.2/4.2
Hegele et al. [2014]	n = 21, retrospective study	6.2/4.4
Retz et al. [2015]	n = 77, prospective study	7.7/–
Castellano et al. [2014]	n = 102, prospective study	10.0/3.9
Palacka et al. [2014]	n = 16, prospective study	5.2/2.3
Summarized	n = 440, prospective and retrospective observations	7.6/4.1
Bellmunt et al. [2009]	n = 259, phase III trial	6.9/3.0

OS, overall survival; PFS, progression-free survival.